SentryOne Introduces Database Monitoring Edition Targeted to Smaller Environments
7.2.2019 17:00:00 EET | Business Wire | Press release
SentryOne launched SQL Sentry Essentials, a new edition of the company’s top-rated SQL Sentry database monitoring product that provides core monitoring capabilities for up to five database targets at $995 per targeted SQL Server instance.
SQL Sentry Essentials includes the most frequently used features for monitoring, diagnosing, and optimizing SQL Server performance. This new edition is ideal for small and medium companies as well as larger organizations that need to monitor specific data systems within their environment.
“SQL Sentry Essentials is a perfect choice when you need to deploy SQL Server performance management at a small scale, or if you need enterprise capabilities but aren’t ready to build the case for an investment in a larger database performance management solution,” said Jason Hall, SentryOne VP of Product Management. “This new edition gives you the crucial information you need to get to the root of your SQL Server performance problems.”
SentryOne introduced SQL Sentry Essentials to meet the industry need for a monitoring solution that provides powerful core monitoring capabilities but excludes advanced features valued by larger enterprises.
“Everyone needs to monitor their databases, but not everyone needs all the advanced features of our flagship product, SQL Sentry,” said Andy Mallon, SentryOne Product Manager. “We’ve distilled the feature list down to the most essential monitoring capabilities, now available as SQL Sentry Essentials. This new edition is a powerful, capable solution for companies who need to monitor up to five instances, all at a very attractive price.”
SQL Sentry Essentials includes five of the most frequently used SQL Sentry features, helping data pros view essential real-time performance metrics, identify high-impact queries that are slowing performance, use proactive notifications to prevent problems, analyze SQL Server blocking and deadlocks, and view Windows resource metrics.
SentryOne customer David Klee, Heraflux Technologies Founder and Chief Architect, said that one of the features included in SQL Sentry Essentials, the Performance Analysis Dashboard, gives actionable information that helps data pros quickly identify and address problems.
“Lots of other utilities provide 'pretty' dashboards that do not provide much meaning,” Klee said. “SentryOne gives you a dashboard that presents vital performance statistics. Anything unusual jumps out at you and helps you refine how you approach that server.”
SQL Sentry Essentials is priced at US$995 per license, which can be applied to one targeted SQL Server instance, plus US$199 for annual maintenance (first year required). Subscription pricing is available at US$50 monthly (annual commitment required).
For more information, visit sentryone.com/sqlsentry-essentials.
About SentryOne
SentryOne empowers Microsoft data
professionals to build, test, document, and monitor SQL Server, Azure
SQL Database, and the Microsoft Data Platform. We help companies
accelerate performance across the data lifecycle with unmatched
scalability, best-in-industry customer support, and the most powerful
data performance management capabilities available. Our team includes a
core group of Microsoft MVPs and staff located in Charlotte, NC,
Jacksonville, FL, Salem, NH, and Dublin, Ireland. Learn more at SentryOne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005104/en/
Contact information
Megan Keller
Communications Manager
media@sentryone.com
Erik Arvidson
Matter for SentryOne
978-518-4542
sentryone@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Third Consecutive Year14.5.2026 07:01:00 EEST | Press release
Corona global has been recognized as the most valuable beer brand in the world for the third consecutive year in Kantar's BrandZ 2026 Most Valuable Global Brands report, released today. Eight out of the top ten most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the best brands in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513211378/en/ In 2025, Corona led AB InBev’s performance, increasing revenue by 8.3% outside of its home market with double-digit volume growth in 30 markets, while Corona Cero delivered strong double-digit volume growth. As the brand celebrated its 100th anniversary, Corona launched its global “Corona 100” platform, including a multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro. Strong momentum continued in Q1 2026, with AB InBev delivering all-time high revenues and volume growt
The Bolivarian Republic of Venezuela Announces the Initiation of a Comprehensive Public Debt Restructuring Process13.5.2026 23:08:00 EEST | Press release
The Bolivarian Republic of Venezuela announces today its decision to initiate a comprehensive restructuring of its external public debt obligations. CONTEXT & RATIONALE Over the past decade, Venezuela's economy has been severely impacted by external shocks – from the end of the commodity super-cycle to foreign sanctions and COVID-19 – resulting in a sharp economic contraction, a protracted default since 2017, and a ballooning of public sector liabilities. The country nonetheless possesses a strong economic potential, including unique hydrocarbon and mineral endowments. A recovery is underway, and Venezuela is committed to accelerating it through a comprehensive reform agenda in support of growth, fiscal sustainability, monetary stabilization, and enhanced governance. Restoring public debt sustainability is central to this agenda: the current debt overhang constrains external financing, limits public investment capacity, and prevents full re-engagement with the international financial s
Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise13.5.2026 22:00:00 EEST | Press release
Boomi, the data activation company for AI, today announced it has signed a letter of intent to acquire Lunar.dev, an innovator in AI and MCP gateway. The proposed acquisition is expected to enrich the Boomi Enterprise Platform and Boomi Connect with advanced capabilities to govern and scale AI usage across enterprise systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513850557/en/ Boomi Announces Intent to Acquire Lunar.dev to Deliver Governed Agent Connectivity Across the Enterprise As organizations move from AI experimentation to production, controlling how agents and AI applications interact with LLMs at scale has become critical. Lunar.dev addresses this need with an AI gateway that delivers granular, policy-driven control over AI interactions, with the visibility, security, and performance required for enterprise environments. These capabilities enable organizations to move from pilot to production with confiden
BeOne Medicines’ BEQALZI ™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma13.5.2026 20:27:00 EEST | Press release
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to BEQALZI™(bee-KAHL-zee; sonrotoclax), a foundational, next-generation BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL), after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor. BEQALZI was designed to enhance BCL2 inhibition—with greater potency, selectivity, and a pharmacologic profile with potential to improve efficacy, tolerability, and convenience over others in the class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513542161/en/ BeOne Medicines' flagship U.S. biologics manufacturing and clinical R&D facility at the Princeton West Innovation Campus in Hopewell, N.J. Michael Wang, M.D., Global Principal Investigator
Boomi Unveils Innovations That Power the Agentic Enterprise13.5.2026 17:30:00 EEST | Press release
Boomi, the data activation company for AI, today announced a major expansion of the Boomi Enterprise Platform at Boomi World 2026, introducing new capabilities across orchestrated agentic workflows, agentic engineering, governed agent connectivity, grounded agent context, and localized agent infrastructure. Together, these innovations are designed to power the agentic enterprise — where agents and humans work together to drive action and operationalize AI at scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260513996223/en/ Boomi Unveils Innovations That Power the Agentic Enterprise The enterprise has reached a defining moment as AI becomes the primary interface for work and MCP emerges as the new standard. While the shift toward a headless, agentic enterprise is inevitable, this vision is colliding with skyrocketing cloud costs and trapped data. For many, layering agents onto a fragmented landscape only magnifies govern
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom